Price | 1W % | 1M % | 3M % | 6M % | 1Y % | YTD % |
|---|---|---|---|---|---|---|
-- | -- | -- | -- | -- | -- | -- |
AI Generated Qualitative Analysis
Your time is precious, so save it. Use AI to get the most important information from the business.
Learn about Aditxt, Inc.
Aditxt, Inc. News
Aug 5, 2025 - prnewswire.com
Evofem CEO Saundra Pelletier Honored with Trailblazing Female Founders Award at STIMULATE Conference
Jul 24, 2025 - businesswire.com
Aditxt's Subsidiary Pearsanta Receives an Invitation to Submit Full Proposal for the U.S. Department of Defense Pilot Award for the Development of its Mitomic® Ovarian Test
Aditxt, Inc. Quantitative Score
About Aditxt, Inc.
Aditxt, Inc., a biotech company, develops technologies focuses on improving the health of the immune system through immune mapping and reprogramming. It develops AditxtScore that allows individuals to understand, manage, and monitor their immune profiles in order to be informed about attacks on or by their immune system; and Apoptotic DNA Immunotherapy, a nucleic acid-based technology that utilizes an approach that mimics the way the body naturally induces tolerance to its own tissues. The company is also developing ADi products for organ transplantation, including skin grafting, autoimmune diseases, and allergies. Aditxt, Inc. has a license agreement with Loma Linda University and Leland Stanford Junior University. The company was formerly known as ADiTx Therapeutics, Inc. and changed its name to Aditxt, Inc. in July 2021. Aditxt, Inc. was incorporated in 2017 and is headquartered in Richmond, Virginia.
Aditxt, Inc. Earnings & Revenue
What’s This Company Really Worth? Find Out Instantly.
Warren Buffett’s go-to valuation method is Discounted Cash Flow (DCF). Our tool makes it effortless — no spreadsheets, just answers in a few clicks.
Aditxt, Inc. Financials
Table Compare
Compare ADTX metrics with: | |||
|---|---|---|---|
Earnings & Growth | ADTX | None | |
EPS (TTM) YoY Growth | -- | -- | |
Revenue (TTM) YoY Growth | -- | -- | |
Valuation (TTM) | ADTX | None | |
Price/Earnings Ratio | -- | -- | |
Price/Sales Ratio | -- | -- | |
Profitability & Efficiency (TTM) | ADTX | None | |
Net Profit Margin | -- | -- | |
Return on Equity | -- | -- | |
Financial Health (TTM) | ADTX | None | |
Debt/Assets Ratio | -- | -- | |
Assets/Liabilities Ratio | -- | -- | |
Aditxt, Inc. Income
Aditxt, Inc. Balance Sheet
Aditxt, Inc. Cash Flow
Aditxt, Inc. Financials Over Time
Analysts Rating
Strong Buy
Buy
Hold
Sell
Strong Sell
Metrics Scores
| Metrics | Score |
|---|---|
| Discounted Cash Flows | Strong Sell |
| Return on Equity | Strong Sell |
| Return on Assets | Strong Sell |
| Debt/Equity Ratio | Sell |
| Price/Earnings Ratio | Strong Sell |
| Price/Book Ratio | Strong Buy |
Price Targets
Disclaimer: This 3rd party analysis information is for reference only and does not constitute investment advice.
Historical Market Cap
Shares Outstanding
Aditxt, Inc. Executives
| Name | Role |
|---|---|
| Mr. Amro A. Albanna | Co-Founder, Chairman & Chief Executive Officer |
| Mr. Thomas J. Farley CPA | Chief Financial Officer |
| Ms. Corinne D. Pankovcin CPA, M.B.A. | Chief Mergers & Acquisitions Officer |
| Dr. Shahrokh Shabahang D.D.S., M.S., Ph.D. | Co-Founder, Chief Innovation Officer, Secretary & Director |
| Ms. Rowena Albanna | Chief Operating Officer |
| Name | Role | Gender | Date of Birth | Pay |
|---|---|---|---|---|
| Mr. Amro A. Albanna | Co-Founder, Chairman & Chief Executive Officer | Male | 1970 | 500K |
| Mr. Thomas J. Farley CPA | Chief Financial Officer | Male | 1974 | 464.62K |
| Ms. Corinne D. Pankovcin CPA, M.B.A. | Chief Mergers & Acquisitions Officer | Female | 1966 | 385.01K |
| Dr. Shahrokh Shabahang D.D.S., M.S., Ph.D. | Co-Founder, Chief Innovation Officer, Secretary & Director | 1964 | 325K | |
| Ms. Rowena Albanna | Chief Operating Officer | Female | 1966 | -- |
Aditxt, Inc. Insider Trades
| Date | 5 Jun |
| Name | PELLETIER SAUNDRA L |
| Role | Director |
| Transaction | Disposed |
| Type | |
| Shares | 0 |
| Date | 15 Oct |
| Name | HRT FINANCIAL LP |
| Role | 10 percent owner |
| Transaction | Acquired |
| Type | P-Purchase |
| Shares | 15636 |
| Date | 16 Oct |
| Name | HRT FINANCIAL LP |
| Role | 10 percent owner |
| Transaction | Disposed |
| Type | S-Sale |
| Shares | 25534 |
| Date | 15 Oct |
| Name | HRT FINANCIAL LP |
| Role | 10 percent owner |
| Transaction | Disposed |
| Type | |
| Shares | 0 |
| Date | 8 Nov |
| Name | Runge Jeffrey W. |
| Role | Director |
| Transaction | Acquired |
| Type | A-Award |
| Shares | 470 |
| Date | Name | Role | Transaction | Type | Shares |
|---|---|---|---|---|---|
| 5 Jun | PELLETIER SAUNDRA L | Director | Disposed | 0 | |
| 15 Oct | HRT FINANCIAL LP | 10 percent owner | Acquired | P-Purchase | 15636 |
| 16 Oct | HRT FINANCIAL LP | 10 percent owner | Disposed | S-Sale | 25534 |
| 15 Oct | HRT FINANCIAL LP | 10 percent owner | Disposed | 0 | |
| 8 Nov | Runge Jeffrey W. | Director | Acquired | A-Award | 470 |